{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:38:29Z","timestamp":1740155909683,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1038\/s41584-023-01003-6","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T17:36:45Z","timestamp":1690393005000},"page":"543-544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insights into juvenile myositis via engineered muscle"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0595-6533","authenticated-orcid":false,"given":"Hanna","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"1003_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","volume":"19","author":"C Papadopoulou","year":"2023","unstructured":"Papadopoulou, C., Chew, C., Wilkinson, M. G. L., McCann, L. & Wedderburn, L. R. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat. Rev. Rheumatol. 19, 343\u2013362 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1003_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/BOR.0000000000000816","volume":"33","author":"H Kim","year":"2021","unstructured":"Kim, H. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy. Curr. Opin. Rheumatol. 33, 371\u2013377 (2021).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1003_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead186","author":"LT Covert","year":"2023","unstructured":"Covert, L. T. et al. Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis. Rheumatology (Oxford) https:\/\/doi.org\/10.1093\/rheumatology\/kead186 (2023).","journal-title":"Rheumatology (Oxford)"},{"key":"1003_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40478-016-0308-5","volume":"4","author":"C Preusse","year":"2016","unstructured":"Preusse, C. et al. Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. Acta Neuropathol. Commun. 4, 45 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"1003_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12955","volume":"31","author":"L Bolko","year":"2021","unstructured":"Bolko, L. et al. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 31, e12955 (2021).","journal-title":"Brain Pathol."},{"key":"1003_CR6","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","volume":"141","author":"L Ladislau","year":"2018","unstructured":"Ladislau, L. et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 141, 1609\u20131621 (2018).","journal-title":"Brain"},{"key":"1003_CR7","doi-asserted-by":"publisher","first-page":"e2108","DOI":"10.1212\/WNL.0000000000200271","volume":"98","author":"L Gallay","year":"2022","unstructured":"Gallay, L. et al. Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis. Neurology 98, e2108\u2013e2119 (2022).","journal-title":"Neurology"},{"key":"1003_CR8","doi-asserted-by":"publisher","first-page":"119416","DOI":"10.1016\/j.biomaterials.2019.119416","volume":"221","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Engineered skeletal muscles for disease modeling and drug discovery. Biomaterials 221, 119416 (2019).","journal-title":"Biomaterials"},{"key":"1003_CR9","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1016\/j.celrep.2018.11.092","volume":"25","author":"S Bersini","year":"2018","unstructured":"Bersini, S. et al. Engineering an environment for the study of fibrosis: a 3d human muscle model with endothelium specificity and endomysium. Cell Rep. 25, 3858\u20133868 (2018).","journal-title":"Cell Rep."},{"key":"1003_CR10","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1021\/acschembio.0c00343","volume":"15","author":"TB Kinder","year":"2020","unstructured":"Kinder, T. B., Dranchak, P. K. & Inglese, J. High-throughput screening to identify inhibitors of the type i interferon-major histocompatibility complex class i pathway in skeletal muscle. ACS Chem. Biol. 15, 1974\u20131986 (2020).","journal-title":"ACS Chem. Biol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01003-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01003-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01003-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:11:38Z","timestamp":1692709898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01003-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-01003-6","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"type":"print","value":"1759-4790"},{"type":"electronic","value":"1759-4804"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"26 July 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.K. is part of a clinical study at NIAMS that received grant support for under a government CRADA from Eli Lilly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}